Soluble Dextrin Fibers Alter the Intestinal Microbiota and Reduce Proinflammatory Cytokine Secretion in Male IL-10–Deficient Mice

Valcheva, Rosica; Hotte, Naomi; Gillevet, Patrick M.; Sikaroodi, Masoumeh; Thiessen, Aducio; Madsen, Karen

doi:10.3945/jn.114.207738

Cited by 38 publications

(25 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The beneficial effects of ingesting high‐fibre diets and SCFAs are also related to the impaired progression of colitis 31 . interleukin (IL)‐10‐deficient mice, which develop colitis spontaneously, have experienced significant amelioration of those symptoms when fed high‐fibre diets 32 . This protection was associated with an increase of butyrate‐producing bacteria as well as the reduction in pro‐inflammatory cytokines IL‐1β, tumor necrosis factor and IL‐23, 32 bolstering the idea that the modulation of gut microbiota so as to bias the microbiota to SCFA‐producing bacteria may favour an anti‐inflammatory profile.…”

Section: Gut Microbiota and Ckdsmentioning

confidence: 99%

The microbiota and chronic kidney diseases: a double‐edged sword

et al. 2016

View full text Add to dashboard Cite

Recent findings regarding the influence of the microbiota in many inflammatory processes have provided a new way to treat diseases. Now, one may hypothesize that the origin of a plethora of diseases is related to the health of the gut microbiota and its delicate, although complex, interface with the epithelial and immune systems. The ‘westernization' of diets, for example, is associated with alterations in the gut microbiota. Such alterations have been found to correlate directly with the increased incidence of diabetes and hypertension, the main causes of chronic kidney diseases (CKDs), which, in turn, have a high estimated prevalence. Indeed, data have arisen showing that the progression of kidney diseases is strictly related to the composition of the microbiota. Alterations in the gut microbiota diversity during CKDs do not only have the potential to exacerbate renal injury but may also contribute to the development of associated comorbidities, such as cardiovascular diseases and insulin resistance. In this review, we discuss how dysbiosis through alterations in the gut barrier and the consequent activation of immune system could intensify the progression of CKD and vice versa, how CKDs can modify the gut microbiota diversity and abundance.

show abstract

Section: Gut Microbiota and Ckdsmentioning

confidence: 99%

The microbiota and chronic kidney diseases: a double‐edged sword

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Prebiotics are defined as non-digestible, selectively fermented ingredients that induce specific changes in the activity and composition of the gut microbiota, providing benefits to host well-being and health [ 87 ]. Addition of soluble dextrin prebiotic fibers to the diet was reported to reduce proinflammatory cytokine secretion and enterocyte injury in male Il10 −/− mice [ 88 ]. Importantly, probiotics can directly stimulate mucin gene expression, synthesis, and secretion to protect the host from pathogenic bacterial invasion [ 89 ].…”

Section: Implications For Clinical Utilitymentioning

confidence: 99%

Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease

Sun

Shen

et al. 2016

Nutrients

View full text Add to dashboard Cite

Recently, numerous studies have shown that disruption of the mucus barrier plays an important role in the exacerbation of inflammatory bowel disease, particularly in ulcerative colitis. Alterations in the mucus barrier are well supported by published data and are widely accepted. The use of fluorescence in situ hybridization and Carnoy’s fixation has revealed the importance of the mucus barrier in maintaining a mutualistic relationship between host and bacteria. Studies have raised the possibility that modulation of the mucus barrier may provide therapies for the disease, using agents such as short-chain fatty acids, prebiotics and probiotics. This review describes changes in the mucus barrier of patients with inflammatory bowel disease and in animal models of the disease. We also review the involvement of the mucus barrier in the exacerbation of the disease and explore the therapeutic potential of modifying the mucus barrier with short-chain fatty acids, prebiotics, probiotics, fatty acid synthase, H2S, neutrophil elastase inhibitor and phophatidyl choline.

show abstract

“…In animal studies, prebiotics alter the gut microbiota and have anti‐inflammatory effects. Soluble dextrin from different sources (corn or tapioca) differentially alters the gut microbiota, thus it is safe to assume the complexity of prebiotic fermentation and the effects of prebiotics on the gut microbiota colonies 108 . When fed a high‐fibre diet or SCFA acetate, mice had a reduced risk of developing colitis 109 , 110 .…”

Section: The Local Effects Of Gut Microbiota On Ibdmentioning

confidence: 99%

“…Soluble dextrin from different sources (corn or tapioca) differentially alters the gut microbiota, thus it is safe to assume the complexity of prebiotic fermentation and the effects of prebiotics on the gut microbiota colonies. 108 When fed a high-fibre diet or SCFA acetate, mice had a reduced risk of developing colitis. 109,110 This could be due to the actions of butyrate on the colonic epithelium, but also the capacity of SCFAs in promoting the numbers and functions of colonic Tregs, thus enabling a state that is more resistant to inflammation.…”

Section: The Local Effects Of Gut Microbiota On Ibdmentioning

confidence: 99%

Bugging inflammation: role of the gut microbiota

Shen

Wong

2016

Clin & Trans Imm

View full text Add to dashboard Cite

The advent of vaccination and improved hygiene have eliminated many of the deadly infectious pathogens in developed nations. However, the incidences of inflammatory diseases, such as inflammatory bowel disease, asthma, obesity and diabetes are increasing dramatically. Research in the recent decades revealed that it is indeed the lack of early childhood microbial exposure, increase use of antibiotics, as well as increase consumption of processed foods high in carbohydrates and fats, and lacking fibre, which wreak havoc on the proper development of immunity and predispose the host to elevated inflammatory conditions. Although largely unexplored and under-appreciated until recent years, these factors impact significantly on the composition of the gut microbiota (a collection of microorganisms that live within the host mucosal tissue) and inadvertently play intricate and pivotal roles in modulating an appropriate host immune response. The suggestion that shifts in the composition of host microbiota is a risk factor for inflammatory disease raises an exciting opportunity whereby the microbiota may also present as a potential modifiable component or therapeutic target for inflammatory diseases. This review provides insights into the interactions between the microbiota and the immune system, how these affect disease phenotypes, and explore current and emerging therapies that target the gut microbiota as potential treatment for inflammatory diseases.

show abstract

Soluble Dextrin Fibers Alter the Intestinal Microbiota and Reduce Proinflammatory Cytokine Secretion in Male IL-10–Deficient Mice

Cited by 38 publications

References 49 publications

The microbiota and chronic kidney diseases: a double‐edged sword

The microbiota and chronic kidney diseases: a double‐edged sword

Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease

Bugging inflammation: role of the gut microbiota

Contact Info

Product

Resources

About